Medivir brings the Q1 webcast forward to 10 a.m. on April 30
STOCKHOLM, April 29, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the company will host the Q1 Quarterly Results webcast tomorrow, April 30, at 10 a.m. CET. The webcast is brought forward as Nasdaq Stockholm closes earlier.
For additional information, please contact Magnus Christensen, CFO, Medivir AB Telephone: +46 8 5468 3100 E-mail: [email protected]
About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a smart, targeted chemotherapy designed to selectively treat liver cancer cells and to minimize side effects. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list. www.medivir.com.
Children's HealthSM and UT Southwestern Medical Center announced a historic gift of $100 million from the Jean and Mack Pogue family in support of the $5 billion new Dallas pediatric campus, unveiled earlier this year. The gift from the Pogue...
Amgen will host a webcasted call for the investment community at 1:00 p.m. PT on Monday, May 20, 2024 following the presentation of new data from TEZSPIRE® in chronic obstructive pulmonary disease (COPD) at the American Thoracic Society (ATS)...
Baltimore Urban Gardening with Students (BUGS), a program operated by The Crossroads School, a Living Classrooms Foundation Charter School, is excited to announce its 26th Annual Youth Farmer's Market taking place on Saturday, May 18th, from 9:00 AM...
DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") , a healthcare technology company focused on brain health using AI, is pleased to announce that it is arranging a private placement of a minimum of $400,000 and a maximum of $650,000 of units...
A new guideline has been issued to help neurologists and other clinicians determine the best antiseizure medications for people with epilepsy who may become pregnant. The guideline is published in the May 15, 2024, online issue of Neurology®, the...
The leading cause of death worldwide is chronic inflammatory diseases. When the body is inflamed and under stress for long periods of time, the body's heart rate increases, increasing the risk of fatality. A new study published in Brain, Behavior and...
